Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
MELBOURNE, Australia, Oct. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma[1], which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (99mTc) and rhenium-188 (188Re). Rhine Pharma was formed following a collaboration between Telix and...
Read more